Regulatory analysis of the integration of oncology pharmaceutical services across the healthcare levels

Abstract This study analyzes the regulatory mechanisms governing the integration of pharmaceutical services between high-complexity oncology care and primary health care within the Brazilian Unified Health System. The fragmented care levels undermine treatment continuity, particularly for oncology patients who require ongoing follow-up across both settings. A document analysis of federal regulations in effect from 1990 to 2024 was conducted to identify barriers and facilitators to this integration. The findings indicate that, although normative guidelines are in place, significant challenges persist, including unequal access to expensive medicines, the lack of integrated health information systems, and discontinuous pharmacotherapeutic follow-up. The study advocates for shared care, emphasizing greater collaboration among healthcare teams as a strategy to streamline pharmacotherapy management and ensure care continuity. It concludes that updated regulatory frameworks and coordinated practices are essential to overcoming a fragmented system and ensuring comprehensive and equitable care within the Brazilian Unified Health System.